CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that
management will present at the following investor conferences in June:
- Jefferies Healthcare Conference, New York, June 7th at 10 a.m. ET
- William Blair Annual Growth Stock Conference, Chicago, June 16th at 10 a.m. CT
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
Contact: Douglas Carlson Vice President, Corporate Development dcarlson@collegiumpharma.com
